TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02910635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volanesorsen
Description: ISIS 304801 is supplied as 200mg of volanesorsen with 1.0mL of solution per vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volanesorsen
Description: ISIS 304801 is supplied as 200mg of volanesorsen with 1.0mL of solution per vial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin Hydrochloride 400 mg tablet administered orally, Single Dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04653935

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management app with all intervention components
Description: A behavioural self-management app, containing multiple cognitive- and behavioural self-management techniques for those living with Sjögren's syndrome. The intervention is comprised of several components and modules that holistically target several key symptoms: fatigue, sleep disturbances, chronic pain, and dryness. The app has been developed using user-centred methods, and is theory- and evidence-based.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-management app with Information component only
Description: self-management app for those with Sjögren's syndrome, includes Symptom and Lifestyle Information, only.
Study: NCT03996083

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise intervention
Description: Strength exercises were focused on lower limb strengthening. Individual bilateral intensities were calculated to estimate one repetition maximum (1-RM) for the leg and arm. This test was performed on the 2nd and 7th weeks of the intervention. A gradual and progressive intensity starting at 40% 1-RM and up 70% 1-RM was used. No external loads were applied to the rest of the exercises due to their complex execution technique and subsequent risk of adverse events. In these cases, training progression was achieved through volume (number of repetitions) and execution velocity increments.~Balance exercises included standing with their feet together, semi-tandem, tandem and one-legged stand positions and moving on to dynamic exercises (circuits, stepping and so on). Difficulty was increased by reducing arm and base support and by varying the type and complexity of exercises. An individualized progression was applied to each participant based on their progress throughout the intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking intervention
Description: To comply with the walking goals, walking distance was calculated based on each participant´s performance on the 6-minute walking test and using a rule of thumb. Therefore, every participant had an itinerary to follow to comply with the minimum walking time each week. Distance rather than time was used with participants for practical reasons and the inability of most of them to measure time. Moreover, time and distance were individually adapted according to each participant´s performance on the previous week.~To ensure that participants complied with the walking goals, each of them (if they were cognitively able) was given a record sheet in which they had to write down their everyday walking routines. In addition, the caregivers were also informed about the walking routines and ensured that those participants who needed close supervision had someone to walk with and filled the sheet of those that were unable to do so.
Study: NCT00590369

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KCI -VAC
Description: Negative pressure wound therapy device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Versatile One (EZCare)
Description: Negative pressure wound therapy device
Study: NCT01351272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate, non-retard
Description: Medication (methylphenidate, non-retard) will be titrated to optimal response within 6 weeks, with a maximum of 10 mg/day in week 1, 20 mg/day in week 2, 30 mg/day in week 3, 40 mg/day in week 4, 50 mg/day in week 5, and 60 mg/day in week 6, unless adverse effects emerged. After successful adjustment, medication will be maintained until week 6. Dosing will be based on at least two-weekly evaluations by a psychiatrist, including an interview with a review of symptoms and side effects, completion of the Clinical Global Impression (CGI) scale and completion of a standardised Side Effects Rating Scale for psychostimulants (SERS). The maximal daily dosage of MPH is 60 mg. Within this double blind study the same procedure is applied for the placebo condition.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03542630

Intervention type: DIAGNOSTIC_TEST
Intervention: salivary MMP8 test
Description: All female participants will make salivary MMP8 test and certain blood parameters to determine systemic inflammatory response

Intervention type: DIAGNOSTIC_TEST
Intervention: salivary MMP8 test
Description: All female participants will make salivary MMP8 test and certain blood parameters to determine systemic inflammatory response

Intervention type: DIAGNOSTIC_TEST
Intervention: salivary MMP8 test
Description: All female participants will make salivary MMP8 test and certain blood parameters to determine systemic inflammatory response

Intervention type: DIAGNOSTIC_TEST
Intervention: salivary MMP8 test
Description: All female participants will make salivary MMP8 test and certain blood parameters to determine systemic inflammatory response

Intervention type: OTHER
Intervention: periodontal examination
Description: Periodontal examination by a specialist of periodontology will be made to all female participants, using periodontal probe and dental mirror.

Intervention type: OTHER
Intervention: periodontal examination
Description: Periodontal examination by a specialist of periodontology will be made to all female participants, using periodontal probe and dental mirror.

Intervention type: OTHER
Intervention: periodontal examination
Description: Periodontal examination by a specialist of periodontology will be made to all female participants, using periodontal probe and dental mirror.

Intervention type: OTHER
Intervention: periodontal examination
Description: Periodontal examination by a specialist of periodontology will be made to all female participants, using periodontal probe and dental mirror.

Intervention type: OTHER
Intervention: blood tests
Description: All female participants who do not have recent blood tests will make new blood tests to determine certain blood parameters.

Intervention type: OTHER
Intervention: blood tests
Description: All female participants who do not have recent blood tests will make new blood tests to determine certain blood parameters.

Intervention type: OTHER
Intervention: blood tests
Description: All female participants who do not have recent blood tests will make new blood tests to determine certain blood parameters.

Intervention type: OTHER
Intervention: blood tests
Description: All female participants who do not have recent blood tests will make new blood tests to determine certain blood parameters.
Study: NCT02487316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib
Description: crizotinib 250mg, oral, bid from day 1 to 18 weeks. cyclophosphamide, 750mg/m2,d1, vincristine, 1.4mg/m2, maximal dose is 2mg d1, doxorubicin, 50mg/m2d1, prednison, 100 mg d1-5) every 3 weeks for up to six cycles.
Study: NCT01901692

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib 800 mg/day orally
Study: NCT04106778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMT310
Description: Topical Powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Topical Powder
Study: NCT05267496

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oscillating positive expiratory pressure device
Description: Patients randomized to the experimental arm of the study will receive an AEROBIKA oscillating positive expiratory pressure device in addition to the standard pulmonary rehabilitation program. The patient will receive instructions pertaining to the use of the device during the first evaluation visit to the rehabilitation service and this information will be reinforced at each follow-up visit. The patient will receive a log book in order to record date and time of use to assess treatment compliance and an instructions and maintenance booklet will be handed out to ensure adequate use of the device.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: Educational ventilatory techniques will be explained in order to re-educate respiratory muscles and increase patient awareness regarding the importance of complying with the exercise schedule to improve muscular strength. Including:~Pre-surgical rehabilitation~* Directed ventilation~* Physical conditioning Post-surgical rehabilitation~* Diaphragmatic mobilization~* Thoracic expansion through incentive flow spirometry

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pulmonary rehabilitation
Description: Educational ventilatory techniques will be explained in order to re-educate respiratory muscles and increase patient awareness regarding the importance of complying with the exercise schedule to improve muscular strength. Including:~Pre-surgical rehabilitation~* Directed ventilation~* Physical conditioning Post-surgical rehabilitation~* Diaphragmatic mobilization~* Thoracic expansion through incentive flow spirometry
Study: NCT04271293

Intervention type: DRUG
Intervention: Edoxaban
Description: Edoxaban will be administered via PEG in patients who are eligible for the anticoagulant treatment according to the current guidelines.
Study: NCT02969135

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive early passive and active movement
Description: Post-surgical physical therapy including active exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Limited early passive movement
Description: Post-surgical physical therapy including passive mobilisation
Study: NCT04284111

Intervention type: DEVICE
Intervention: Orthokeratology lenses
Description: Orthokeratology lenses
Study: NCT01194596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation advice
Description: Brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine), will be given in both arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spirometry and smoking cessation advice
Description: Intervention group: will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine) together with a detailed and structured discussion of the spirometric results.
Study: NCT03573674

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CE - Cognitive Ergonomics (KERGO)
Description: CE Cognitive ergonomics Intervention deals with themes such as disruptions, interruptions, information overload.~A cognitive behaviour change method was applied in the intervention tasks. Both the tasks of discussing and developing new practices within the groups of individuals and the tasks for individuals were constructed to utilize mental contrasting with implementation intentions (MCII) method

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RS - Recovery Support (KUORMA)
Description: RS Recovery Support / Stress Management Intervention deals with themes such as workload management, recovery, work-family balance.~A cognitive behaviour change method was applied in the intervention tasks. Both the tasks of discussing and developing new practices within the groups of individuals and the tasks for individuals were constructed to utilize mental contrasting with implementation intentions (MCII) method
Study: NCT01418521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balanced hydroxyethyl starch solution
Description: Patients receiving Tetraspan 6% ( a balanced 3rd generation Hydroxyethyl starch)for volume replacement after elective cardiac surgery as needed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer- albumin
Description: Patients receiving lactated ringer-albumin solution for volume replacement after cardiac surgery
Study: NCT01788878

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: A first series of questionnaires will be given by the investigator at patients before treatment (inclusion visit) and then the questionnaires will be given at the follow-up visits planned at 6 months, 12 months and 18 months.~Medical data will be collected via the CRF.
Study: NCT04194450

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone monoester
Description: Acute ingestion of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate prior to assessment of outcomes.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Acute ingestion of taste-matched placebo prior to assessment of outcomes.
Study: NCT00575666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin or Placebo
Description: intranasal, 40IU, 4 times daily
Study: NCT01365052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111)
Description: 2 capsules each containing naproxen sodium 220 mg /diphenhydramine hydrochloride (DPH) 25 mg are taken orally with a full glass of water approximately 30 minutes prior to bedtime for 10 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo capsules are taken orally with a full glass of water 30 minutes prior to bedtime for 10 consecutive days
Study: NCT03342677

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Primovist MRI
Description: Utility of Gd-EOB-DTPA (Primovist) enhanced Liver MRI in HCC detection and characterization in cirrhotic patients will be studied.
Study: NCT00575666

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin or Placebo
Description: intranasal, 40IU, 4 times daily
Study: NCT00518180

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novartis Meningococcal ACWY Conjugate Vaccine
Description: One dose of vaccine administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tdap Vaccine
Description: One dose of vaccine administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novartis Meningococcal ACWY Conjugate Vaccine
Description: One dose of vaccine administered intramuscularly
Study: NCT02554240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5202 20mg
Description: once a week, intra-articular injection, for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5202 10mg
Description: once a week, intra-articular injection, for 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Na Hyaluronate 20mg
Description: once a week, intra-articular injection, for 3 weeks
Study: NCT00535977

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Broccoli
Description: 400g ITC-enriched broccoli per week for 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Peas
Description: 400g frozen garden peas per week for 12 months
Study: NCT00652301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe
Description: ezetimibe 10 mg tablet. Duration of Treatment 31 Weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ezetimibe
Description: ezetimibe 10 mg tablet. Duration of Treatment 31 Weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Placebo (unspecified)
Description: matching placebo tablet. Duration of Treatment 31 Weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Placebo (unspecified)
Description: matching placebo tablet. Duration of Treatment 31 Weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo (unspecified)
Description: matching placebo tablet. Duration of Treatment 31 Weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: simvastatin 20 mg tablet. Duration of Treatment 31 Weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: simvastatin 20 mg tablet. Duration of Treatment 31 Weeks.
Study: NCT04477538

Intervention type: OTHER
Intervention: Post-mastectomy breast reconstruction physical well-being survey
Description: -The survey will ascertain: function status (BREAST Q - Physical Well Being Module and PROMIS upper extremity function), former interaction with physical or occupational therapy, amount of narcotics taken weekly due to chest/neck/breast pain, amount of Tylenol or similar anti-inflammatories taken weekly due to chest/neck/breast pain, and amount of muscle relaxants taken weekly due to chest/neck/breast pain.

Intervention type: OTHER
Intervention: Post-mastectomy breast reconstruction physical well-being survey
Description: -The survey will ascertain: function status (BREAST Q - Physical Well Being Module and PROMIS upper extremity function), former interaction with physical or occupational therapy, amount of narcotics taken weekly due to chest/neck/breast pain, amount of Tylenol or similar anti-inflammatories taken weekly due to chest/neck/breast pain, and amount of muscle relaxants taken weekly due to chest/neck/breast pain.
Study: NCT01287052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: Once consent is obtained, the research assistant will notify the charge RN and MD of the patient's study participation. The patient will then be placed in a treatment room and nitrous oxide will be administered per the existing protocol. Each participant will be given nitrous oxide until he/she reports a pain score of zero or up to fifteen minutes. Study subjects will be asked to rate their pain on a scale of 0-10 before the treatment and after the treatment, the time duration of administering nitrous oxide will be recorded. In addition, the pain scores at 30, 60, 90, and 120 minutes post baseline measurement will be collected in order to evaluate the sustained effect of nitrous oxide in treating acute migraine pain. Someone from the study will also make a follow-up phone call 24 - 48 hours to see if pain relief persisted.
Study: NCT02315391

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: isolated whey protein
Description: isolated whey protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: micellar whey protein
Description: micellar whey protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: micellar whey protein
Description: micellar whey protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: glycine
Description: glycine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: glycine
Description: glycine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: citrulline
Description: citrulline
Study: NCT02984124

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informed Assent Discussion
Description: Participants randomized to the intervention arm will participate in a discussion about CPR with a study doctor that follows these steps:~1. Patient's values and preferences for therapies and outcomes elicited from patient and family; overall therapeutic goals formulated~2. Description of CPR and dying process provided~3. Personalized explanation provided about probable lack of achieving any reasonable therapeutic goal with CPR (i.e. why s/he is a poor candidate for CPR due to underlying illness)~4. Patient and family informed that due to severe underlying illness and high likelihood that CPR will be burdensome/harmful and will not provide benefit, CPR will not be offered unless they disagree (except in rare circumstance where overall therapeutic goals from step 1 are to preserve life regardless of quality of that life) Assessment of patient's and family's understanding of issues discussed; patients may actively disagree and request CPR be performed, but CPR not explicitly offered

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care with Attention Control
Description: Participants who are randomized to the usual care arm will receive a friendly visit in the hospital from research personnel to ask if they have any questions or concerns. Follow up assessments and time windows will be explained. Importance of their participation in the study will be emphasized.
Study: NCT04411446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 5 capsules of 100.000 UI Vitamin D orally given all at once. One dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 capsules of containing placebo orally given all at once. One dose.
Study: NCT01517542

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Counseling
Description: 2 groups: 1 with nutritional counseling and other with usual diet without nutritional counseling
Study: NCT06140745

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0 ppm Fluoride Dentifrice 1
Description: Each subject will use this product during one of the five treatment periods in the crossover study design.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1100 ppm NaF Fluoride Dentifrice
Description: Each subject will use this product during one of the five treatment periods in the crossover study design.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1500 ppm NaMFP Fluoride Dentifrice
Description: Each subject will use this product during one of the five treatment periods in the crossover study design.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 0 ppm Fluoride Dentifrice 2
Description: Each subject will use this product during one of the five treatment periods in the crossover study design.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 0 ppm Fluoride Dentifrice 3
Description: Each subject will use this product during one of the five treatment periods in the crossover study design.
Study: NCT03946813

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous PRP preparation
Description: For each patient, autologous PRP preparation havs to be injected to both ovaries and ultrasound (US) guide
Study: NCT04405063

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel Coated PTCA Balloon Catheter
Description: Drug coated balloon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel Coated PTCA Balloon Catheter
Description: Drug coated balloon